DSHNHL 1999-1 (RICOVER-60 = rituximab plus CHOP in patients over 60)

Study Group
German High Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

The goal of the study was to evaluate the therapeutic efficacy of the Monoclonal anti-CD20 Antibody Rituximab and the increase of chemotherapy cycles from 6 to 8.


RICOVER-60 is a randomised study comparing 6 and 8 cycles of chemotherapy with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 14-day intervals (CHOP-14), both with or without the monoclonal anti-CD20 antibody Rituximab in patients aged 61 to 80 years with Aggressive Non-Hodgkin’s Lymphoma.

Founding Year
German Cancer Aid
Dr. Mildred-Scheel-Foundation
Scientific Speaker
Prof. Dr. G. Held
Scientific Speaker Institution

Studiensekretariat Homburg
Universität des Saarlandes
66421 Homburg

Scientific Speaker eMail
Dr. Viola Pöschel
Coordinator eMail
Biometry and Data Management
Marita Ziepert
Biometry and Data Management eMail
Registration Number
National Cancer Institute: NCT00052936 and as EU-20243
Human Disease Ontology Concept